- Home
- Publications
- Publication Search
- Publication Details
Title
How selective are clinical CDK4/6 inhibitors?
Authors
Keywords
-
Journal
MEDICINAL RESEARCH REVIEWS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-11
DOI
10.1002/med.21769
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
- (2020) Niall A. Anderson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes
- (2020) Hirotsugu Hino et al. CANCER SCIENCE
- Cyclin D–CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB
- (2019) Amy E. Schade et al. ONCOGENE
- PIM kinase inhibitors: Structural and pharmacological perspectives
- (2019) Vivek Asati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical characterization of SHR 6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
- (2019) Fei Long et al. CANCER SCIENCE
- Selective Degradation of CDK6 by a Palbociclib Based PROTAC
- (2019) Sandeep Rana et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
- (2019) Baishan Jiang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
- (2019) Ann Lin et al. Science Translational Medicine
- Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
- (2019) J M Weiss et al. ANNALS OF ONCOLOGY
- 344PA phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours
- (2019) B Xu et al. ANNALS OF ONCOLOGY
- p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
- (2019) Keelan Z. Guiley et al. SCIENCE
- Potential Pharmacological Inhibitors Of Pim Kinase Under Clinical Trials
- (2018) Gomathi Priya Jeyapal et al. Anti-Cancer Agents in Medicinal Chemistry
- CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
- (2018) Mary E. Klein et al. CANCER CELL
- Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
- (2018) Teemu P Miettinen et al. EMBO JOURNAL
- The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
- (2018) Daniele Cretella et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
- (2018) S Parylo et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- How selective are pharmacological inhibitors of cell cycle-regulating cyclin-dependent kinases?
- (2018) Radek Jorda et al. JOURNAL OF MEDICINAL CHEMISTRY
- Profile of abemaciclib and its potential in the treatment of breast cancer
- (2018) James M Martin et al. OncoTargets and Therapy
- Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
- (2018) Jessica L.F. Teh et al. CLINICAL CANCER RESEARCH
- Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017
- (2018) Joost C.M. Uitdehaag et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
- (2018) Sunkyu Kim et al. Oncotarget
- Palbociclib-induced autophagy and senescence in gastric cancer cells
- (2017) Claudio A. Valenzuela et al. EXPERIMENTAL CELL RESEARCH
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
- (2017) Jiayuan Wang et al. Journal of Translational Medicine
- The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells
- (2017) Noriyoshi Iriyama et al. LEUKEMIA & LYMPHOMA
- Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling
- (2017) Emily M. Cousins et al. MOLECULAR CANCER RESEARCH
- Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner
- (2017) Feng-Shu Hsieh et al. Molecular Oncology
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival
- (2017) Haizhen Wang et al. NATURE
- Non-kinase targets of protein kinase inhibitors
- (2017) Lenka Munoz NATURE REVIEWS DRUG DISCOVERY
- Drug repurposing in cancer
- (2017) Linda Sleire et al. PHARMACOLOGICAL RESEARCH
- The target landscape of clinical kinase drugs
- (2017) Susan Klaeger et al. SCIENCE
- CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
- (2017) Bahar Laderian et al. SEMINARS IN ONCOLOGY
- ATRX is a regulator of therapy induced senescence in human cells
- (2017) Marta Kovatcheva et al. Nature Communications
- CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
- (2017) Smruthi Vijayaraghavan et al. Nature Communications
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
- (2017) Jeffrey Small et al. Oncotarget
- Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
- (2017) John E. Bisi et al. Oncotarget
- Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
- (2017) Raquel Torres-Guzmán et al. Oncotarget
- Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy
- (2017) Yukiya Sako et al. Scientific Reports
- Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells
- (2017) Mara A. Bonelli et al. NEOPLASIA
- A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence
- (2016) M. Acevedo et al. CANCER RESEARCH
- Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
- (2016) A. Yoshida et al. CANCER RESEARCH
- FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2016) A. J. Walker et al. CLINICAL CANCER RESEARCH
- Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
- (2016) Julien Bollard et al. GUT
- Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
- (2016) J. E. Bisi et al. MOLECULAR CANCER THERAPEUTICS
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
- (2016) Jinfang Zhang et al. MOLECULAR CELL
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
- (2016) Per Hydbring et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Family-wide Structural Analysis of Human Numb-Associated Protein Kinases
- (2016) Fiona J. Sorrell et al. STRUCTURE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
- (2016) Jorge Franco et al. Cell Reports
- Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer
- (2015) Natalia J. Sumi et al. ACS Chemical Biology
- FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2015) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the Pim kinases in multiple myeloma
- (2015) N A Keane et al. Blood Cancer Journal
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway
- (2015) Ge Qin et al. Oncotarget
- The emerging role of CaMKII in cancer
- (2015) Yan-yang Wang et al. Oncotarget
- MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
- (2015) Marta Kovatcheva et al. Oncotarget
- Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
- (2015) Marion Peyressatre et al. Cancers
- Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
- (2014) M. A. Dickson CLINICAL CANCER RESEARCH
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
- (2014) Anil M Narasimha et al. eLife
- Cyclin-dependent kinases
- (2014) Marcos Malumbres GENOME BIOLOGY
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion
- (2013) Olga V. Leontieva et al. CELL CYCLE
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
- (2013) D. M. Molina et al. SCIENCE
- Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma
- (2012) Q. Yang et al. BLOOD
- The Requirement for Cyclin D Function in Tumor Maintenance
- (2012) Yoon Jong Choi et al. CANCER CELL
- Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
- (2012) Catherine M. Sawai et al. CANCER CELL
- CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis
- (2012) Claudia Capparelli et al. CELL CYCLE
- The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression
- (2012) S. Sadasivam et al. GENES & DEVELOPMENT
- Cdk4/6 Inhibition Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
- (2012) F. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Hypoxia suppresses conversion from proliferative arrest to cellular senescence
- (2012) O. V. Leontieva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Driving the Cell Cycle Through Metabolism
- (2011) Ling Cai et al. Annual Review of Cell and Developmental Biology
- A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
- (2011) Lars Anders et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
- (2009) Ji Luo et al. CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now